Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NightstaRx closes $45mm Series C round

Executive Summary

NightstaRx Ltd. (gene therapies for inherited retinal diseases) raised $45mm in its Series C financing to first-time backers Wellington Management Company and Redmile Group, which were joined by returning shareholders Syncona and New Enterprise Associates. The company will use the funds for pipeline development, including a Phase III trial of lead compound NSRREP1 for choroideremia, a Phase I/II study of NSRRPGR for X-linked retinitis pigmentosa, and a Phase I/II trial of a candidate for an inherited form of macular dystrophy.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies